CNTX trades 3064.6% below Wall Street's consensus target of $5.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CNTX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 17, 2026, Context Therapeutics Inc. (CNTX) has a Wall Street consensus price target of $5.25, based on estimates from 6 covering analysts. With the stock currently trading at $0.17, this represents a potential upside of +3064.6%. The company has a market capitalization of $15M.
Analyst price targets range from a low of $4.50 to a high of $6.00, representing a 29% spread in expectations. The median target of $5.25 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CNTX trades at a trailing P/E of -0.4x. Analysts expect EPS to grow +19.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
AGENAgenus Inc. | $262M | $6.29 | $25.00 | +297.5% | Buy | 23.5x | 12 |
IMVTImmunovant, Inc. | $6.9B | $33.28 | $40.00 | +20.2% | Buy | — | 23 |
ONCOOnconetix, Inc. | $1M | $2.91 | — | — | — | — | — |
TPVGTriplePoint Venture Growth BDC Corp. | $153M | $3.78 | $5.00 | +32.3% | Hold | 4.4x | 12 |
AGIOAgios Pharmaceuticals, Inc. | $1.8B | $30.15 | $40.67 | +34.9% | Buy | — | 29 |
SNDXSyndax Pharmaceuticals, Inc. | $809M | $9.13 | $35.60 | +289.9% | Buy | — | 22 |
RCUSArcus Biosciences, Inc. | $2.1B | $16.86 | $40.67 | +141.2% | Buy | — | 18 |
PRMEPrime Medicine, Inc. | $757M | $4.19 | $7.50 | +79.0% | Buy | — | 10 |
RVMDRevolution Medicines, Inc. | $35.5B | $166.87 | $253.47 | +51.9% | Buy | — | 25 |
ILMNIllumina, Inc. | $30.0B | $198.00 | $252.73 | +27.6% | Buy | 36.6x | 50 |
Quick answers to the most common questions about buying CNTX stock.
The consensus Wall Street price target for CNTX is $5.25, representing 3064.6% upside from the current price of $0.1659. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CNTX has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $5.25 implies 3064.6% upside from current levels.
CNTX's current price is $0.1659 with a consensus target of $5.25 (3064.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for CNTX, while the most conservative target is $4.5. The consensus of $5.25 represents the median expectation. These targets typically reflect 12-month expectations.
CNTX is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CNTX stock forecast based on 6 Wall Street analysts shows a consensus price target of $5.25, with estimates ranging from $4.5 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CNTX, with a "Buy" consensus rating and $5.25 price target (3064.6% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CNTX analyst price targets range from $4.5 to $6, a 29% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.25 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.